Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents
Authors
Keywords
-
Journal
European Journal of Preventive Cardiology
Volume -, Issue -, Pages 204748731983150
Publisher
SAGE Publications
Online
2019-02-19
DOI
10.1177/2047487319831500
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
- (2019) Eeva Sliz et al. CIRCULATION
- Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial
- (2019) Salim S. Virani et al. CIRCULATION
- Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
- (2019) Stefano Spolitu et al. CIRCULATION RESEARCH
- Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- (2018) Michael D. Shapiro et al. ANNALS OF INTERNAL MEDICINE
- Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?
- (2018) M. Ruscica et al. ANNALS OF MEDICINE
- PCSK9 antagonists and inflammation
- (2018) Massimiliano Ruscica et al. ATHEROSCLEROSIS
- PCSK9 inhibitors in clinical practice: Expectations and reality
- (2018) Željko Reiner ATHEROSCLEROSIS
- Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials
- (2018) Dean J. Kereiakes et al. ATHEROSCLEROSIS
- Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
- (2018) Marja-Riitta Taskinen et al. ATHEROSCLEROSIS
- Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders
- (2018) Massimiliano Ruscica et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Inflammatory and Cholesterol Risk in the FOURIER Trial
- (2018) Erin A. Bohula et al. CIRCULATION
- PCSK9
- (2018) Michael D. Shapiro et al. CIRCULATION RESEARCH
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
- (2018) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- The ever-expanding saga of the proprotein convertases and their roles in body homeostasis
- (2018) Nabil G. Seidah et al. CURRENT OPINION IN LIPIDOLOGY
- Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
- (2018) Petra El Khoury et al. DIABETES OBESITY & METABOLISM
- PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
- (2018) Lorenzo Da Dalt et al. EUROPEAN HEART JOURNAL
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- Inclisiran for the treatment of dyslipidemia
- (2018) Toshiyuki Nishikido et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PPAR Agonists and Metabolic Syndrome: An Established Role?
- (2018) Margherita Botta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
- (2018) Benoit J. Arsenault et al. Journal of Clinical Lipidology
- Relationship between “LDL-C”, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide
- (2018) Nicholas J. Viney et al. Journal of Clinical Lipidology
- Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics
- (2018) Marie-Soleil Gauthier et al. Journal of Clinical Lipidology
- The Role of Nutraceuticals in Statin Intolerant Patients
- (2018) Maciej Banach et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 as a Positive Modulator of Platelet Activation
- (2018) Marina Camera et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper
- (2018) Andrea Poli et al. PHARMACOLOGICAL RESEARCH
- Present therapeutic role of cholesteryl ester transfer protein inhibitors
- (2018) Nicola Ferri et al. PHARMACOLOGICAL RESEARCH
- PCSK9 induces a pro-inflammatory response in macrophages
- (2018) Chiara Ricci et al. Scientific Reports
- A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes
- (2018) Safi U Khan et al. European Journal of Preventive Cardiology
- Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice
- (2018) José Tuñón et al. European Journal of Preventive Cardiology
- Prevention of cardiovascular disease: Much more is needed
- (2018) Guy G De Backer European Journal of Preventive Cardiology
- Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
- (2018) L. A. Leiter et al. DIABETIC MEDICINE
- Impact of Lipids on Cardiovascular Health
- (2018) Brian A. Ference et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients
- (2018) Maria G Zenti et al. European Journal of Preventive Cardiology
- Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels
- (2018) Marc S. Sabatine et al. JAMA Cardiology
- Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
- (2018) Lawrence A. Leiter et al. DIABETES CARE
- The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption
- (2018) Günther Silbernagel et al. JOURNAL OF LIPID RESEARCH
- PCSK9 Involvement in Aortic Valve Calcification
- (2018) Paolo Poggio et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of Evolocumab on Coronary Plaque Composition
- (2018) Stephen J. Nicholls et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- (2017) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- Bococizumab for the treatment of hypercholesterolaemia
- (2017) Nicola Ferri et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Bococizumab for the treatment of hypercholesterolaemia
- (2017) Nicola Ferri et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PPAR-α agonists are still on the rise: an update on clinical and experimental findings
- (2017) Nicola Ferri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
- (2017) Savvas Hadjiphilippou et al. HEART
- Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters
- (2017) Bin Dong et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
- (2017) Valentina Spigoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lipid Lowering Therapy and Circulating PCSK9 Concentration
- (2017) Tsuyoshi Nozue Journal of Atherosclerosis and Thrombosis
- PCSK9 and infection: A potentially useful or dangerous association?
- (2017) Farzad Khademi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
- (2017) Anastasia Khvorova NEW ENGLAND JOURNAL OF MEDICINE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1
- (2017) Nicola Ferri et al. PHARMACOLOGICAL RESEARCH
- Regulation of PCSK9 by nutraceuticals
- (2017) Amir Abbas Momtazi et al. PHARMACOLOGICAL RESEARCH
- Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management
- (2017) T.P. Johnston et al. PHARMACOLOGICAL RESEARCH
- Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
- (2017) Ivan Pećin et al. European Journal of Preventive Cardiology
- Association Between Smoking and Serum GlycA and High‐Sensitivity C‐Reactive Protein Levels: The Multi‐Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil)
- (2017) Sina Kianoush et al. Journal of the American Heart Association
- Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study
- (2017) Massimiliano Ruscica et al. Journal of the American Heart Association
- The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina
- (2017) Jian Zhang et al. Journal of Thoracic Disease
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
- (2017) Maria Pia Adorni et al. Therapeutics and Clinical Risk Management
- Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
- (2017) Parisa Naeli et al. Frontiers in Genetics
- Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
- (2017) Nihar R. Desai et al. JAMA Cardiology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Liver fat accumulation is associated with circulating PCSK9
- (2016) Massimiliano Ruscica et al. ANNALS OF MEDICINE
- PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement
- (2016) Nicola Ferri et al. ATHEROSCLEROSIS
- PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
- (2016) Jin M. Cheng et al. ATHEROSCLEROSIS
- Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
- (2016) Charalambos Vlachopoulos et al. ATHEROSCLEROSIS
- Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate
- (2016) FD Richard Hobbs et al. BMC Medicine
- Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
- (2016) Josefa Girona et al. Cardiovascular Diabetology
- No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- (2016) Helen M. Colhoun et al. EUROPEAN HEART JOURNAL
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Determining When to Add Nonstatin Therapy
- (2016) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence
- (2016) Nicola Ferri et al. Translational Research
- Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: A randomised study
- (2016) Christina B. Graversen et al. VASCULAR PHARMACOLOGY
- Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia
- (2015) Amit V. Khera et al. AMERICAN JOURNAL OF CARDIOLOGY
- Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study
- (2015) Toru Miyoshi et al. American Journal of Cardiovascular Drugs
- Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary PreventionSignificance
- (2015) Yiming M. Zhu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
- (2015) A. Sahebkar et al. DIABETES OBESITY & METABOLISM
- Prognostic value of PCSK9 levels in patients with acute coronary syndromes
- (2015) Baris Gencer et al. EUROPEAN HEART JOURNAL
- Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
- (2015) Paul M. Ridker et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line
- (2015) Massimiliano Ruscica et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
- (2015) John S. Millar et al. JOURNAL OF CLINICAL INVESTIGATION
- Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice
- (2015) Vikram Ravindra Shende et al. JOURNAL OF LIPID RESEARCH
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs
- (2014) Marianne Abifadel et al. Current Atherosclerosis Reports
- The Epigenetic Drug 5-Azacytidine Interferes with Cholesterol and Lipid Metabolism
- (2014) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sterol Regulatory Element-binding Protein (SREBP) Cleavage Regulates Golgi-to-Endoplasmic Reticulum Recycling of SREBP Cleavage-activating Protein (SCAP)
- (2014) Wei Shao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition ofPCSK9Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway
- (2014) Bin Dong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
- (2014) Yan Zhang et al. Lipids in Health and Disease
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
- (2014) Christian Werner et al. VASCULAR PHARMACOLOGY
- Comparison of Effects of Pitavastatin Versus Pravastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Statin-Naive Patients With Coronary Artery Disease
- (2013) Tsuyoshi Nozue et al. AMERICAN JOURNAL OF CARDIOLOGY
- Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
- (2013) Hagai Tavori et al. CIRCULATION RESEARCH
- Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9
- (2013) Yuan-Lin Guo et al. CLINICAL DRUG INVESTIGATION
- FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression
- (2013) Rongya Tao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus
- (2013) Massimiliano Ruscica et al. Journal of Clinical Lipidology
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects
- (2013) Chan Joo Lee et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Statins in the primary prevention of cardiovascular disease
- (2013) Željko Reiner Nature Reviews Cardiology
- Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
- (2013) Heiner K. Berthold et al. PLoS One
- Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
- (2013) Frederick Raal et al. Journal of the American Heart Association
- The novel function of HINFP as a co-activator in sterol-regulated transcription ofPCSK9in HepG2 cells
- (2012) Hai Li et al. BIOCHEMICAL JOURNAL
- Loss- and Gain-of-function PCSK9 Variants
- (2012) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
- (2012) Livia Pisciotta et al. Lipids in Health and Disease
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study
- (2011) Tohru Noguchi et al. ATHEROSCLEROSIS
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia
- (2011) Fabian Chen et al. BIOMARKERS
- Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
- (2011) J. Mayne et al. CLINICAL CHEMISTRY
- Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
- (2011) Robert J Konrad et al. Lipids in Health and Disease
- Proprotein Convertases in Health and Disease
- (2011) Andrew W. Artenstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
- (2010) Lena Persson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients
- (2010) P. Costet et al. ATHEROSCLEROSIS
- Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients
- (2010) D. C. Chan et al. DIABETES OBESITY & METABOLISM
- In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9
- (2010) Rachid Essalmani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
- (2010) Taichi Yamamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
- (2010) André J. Tremblay et al. JOURNAL OF LIPID RESEARCH
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
- (2010) Greg Welder et al. JOURNAL OF LIPID RESEARCH
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
- (2009) Hai Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
- (2009) Jason S. Troutt et al. JOURNAL OF LIPID RESEARCH
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- HNF1α and SREBP2 are important regulators of NPC1L1 in human liver
- (2009) Camilla Pramfalk et al. JOURNAL OF LIPID RESEARCH
- Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants
- (2009) Sekar Kathiresan et al. NATURE GENETICS
- Berberine decreases PCSK9 expression in HepG2 cells
- (2008) Jamie Cameron et al. ATHEROSCLEROSIS
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- N-3 polyunsaturated fatty acid regulation of hepatic gene transcription
- (2008) Donald B Jump CURRENT OPINION IN LIPIDOLOGY
- The activation and physiological functions of the proprotein convertases
- (2008) N SEIDAH et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
- (2008) Sanae Kourimate et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started